Wonder drug Dasatinib gives hopes to leukemia patients
The company Bristol-Myers Squibb Co at Boston told the press that the ... This drug is very effective in the decreasing the leukemia cells fr...Chronic myeloid leukemia (CML) is usually presented in three diffe...Out of the 107 patients in the accelerated stage 31% who did not rea...Out of the 74% in the blast stage (aggressive form) 29% of the patie...
The company Bristol-Myers Squibb Co at Boston told the press that the drug Dasatinib has led to reduction in the number of patients with Chronic myeloid leukemia (CML).//
This drug is very effective in the decreasing the leukemia cells from the bone marrow than the previously used drug Gleevec.
Chronic myeloid leukemia (CML) is usually presented in three different stages –
Chronic stage, accelerated stage and the blast stage.
Dasatinib was tried on all these stages of leukemia patients and the results were
Out of the186 patients who are in the chronic stage, 45% of the patients attained complete elimination of the leukemia cells from the marrow.
Out of the 107 patients in the accelerated stage 31% who did not react to Gleevec responded positively to Dasatinib.
Out of the 74% in the blast stage (aggressive form) 29% of the patients attained complete elimination of the leukemia cells.
This is a boon to all those patients who do not react to Gleevec which is the treatment for Leukemia.
This drug will soon reach the markets by the end of the current year or the beginning of the next year.
Gleevec was a Swiss product and in 2001after approved by the Food and Drug Administration, made to the markets as the drug which attacks the BCR-ABL protein which results in the abnormal rise of leukocytes.
But with this drug some patients (20% of CML) did not respond to the drug or initially responded but later became resistant to the drug.
The mechanism of the drug action is that it attacks and prevents several proteins (BCR-ABL & SRC) in the same time. SRC is believed to help the leukemia cells to take the alternate pathway and become resistant to Gleevec, but Dasatinib prevents the action of SRC.
The toxicity level of Dasatinib is not more than Gleevec and it has to be brought in to the market for commercial use as the statistics show that in the current year the number of ch '"/>
(Date:6/19/2013)... Middle market merger and acquisition (M&A) ... as cash rich buyers seek to place their capital ... M&A transactions have a good deal in common. The ... history and quality of the target company’s earnings. Potential ... due diligence involves a middle market company, whose value ...
(Date:6/19/2013)... Faith4Kidz is starting a new fundraising effrt to ... like help showing support for kids to learn how to ... Check out the website, http://www.gracenfaith.com to see Faith4Kidz ... white and blue stars as a symbol of our country ... well as the stars we should encourage our children to ...
(Date:6/19/2013)... Francisco, CA (PRWEB) June 19, 2013 ... Pharmacy and Drug Retailer industry has been growing ... $42.7 billion in 2013. Many factors have supported the ... demand for drugs retailed by drugstores; relatively higher drug ... , Additionally, the government's support for the development of ...
(Date:6/18/2013)... June 19, 2013 Consumer injury attorney ... other law firms have launched a new website for ... by dialysis. The website is http://www.DialysisLawsuitAttorneys.com . , ... to begin offering legal services to people who may ... and NaturaLyte, or who may have suffered injuries due ...
(Date:6/18/2013)... June 19, 2013 oBand Surgery Centers, ... are holding complimentary weight loss seminars in Los Angeles ... can be accessed at their official website. oBand Surgery ... recovery time. Their highly skilled panel of surgeons and ... , A senior executive working with oBand Surgery ...
... has a love-hate relationship with iron. Just the right amount is ... brain diseases like Alzheimer,s and Parkinson,s. Science knows ... women. These higher levels may be part of the explanation for ... But why do women have less iron in ...
... to perform everyday activities. This is not primarily due to ... was previously believed new research from the University of ... initiate and complete a task towards a specific goal. ... normally results in a degree of paralysis in the lower ...
... will discuss scientific studies of mutual interests and explore ... Oct. 24-26. The Ohio State University Medical Center is ... first of its kind between the two countries. , ... countries are expected to speak at the event that ...
... providers assess blood and tissue type as well as ... research indicates that checklist might also need to include ... shown the time of day transplant surgery is performed ... dysfunctional internal clocks is the first correlating circadian clocks ...
... 4 (HealthDay News) -- Readmission rates have increased in ... the country,s most elite academic medical centers, new research ... to the hospital within 30 days of being discharged ... as hospitals brace for penalties -- reduced payments for ...
... shows that exposure to stressors in the Neonatal Intensive ... brain structure and function of very preterm infants. According ... Neurology , a journal published by Wiley-Blackwell on behalf ... infants who experienced early exposure to stress displayed decreased ...
(Date:6/18/2013)... , Safinamide significantly improves ... as add-on to levodopa Safinamide is ... in fluctuating PD patients as add-on to levodopa ... ("Newron"), a research and development company focused on ... Zambon S.p.A., a pharmaceutical company strongly committed to ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
(Date:6/18/2013)... 2013 Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share. In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
... GenVec, Inc. (Nasdaq: GNVC ) will report financial ... 2011 on Thursday, March 15, 2012, before the U.S. financial ... and conference call at 10:00 a.m. EDT to discuss the ... outlook. To listen to the live conference ...
... release of System 7 – the next generation of heavy ... such as hip and knee replacements. System 7 offers the ... and highest performing power tool system ever from Stryker. ... heavy duty power tools in 1982, and has built a ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
20L...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....